UK markets closed

LVTX Oct 2024 7.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
At close: 01:47PM EDT
Full screen
Previous close0.2000
Open0.2000
Bid0.0000
Ask0.6000
Strike7.50
Expiry date2024-10-18
Day's range0.2000 - 0.2000
Contract rangeN/A
Volume10
Open interest362
  • GlobeNewswire

    LAVA Announces Annual Meeting of Shareholders

    UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST. All relevant documents and information relating to the annual general meeting, including the notice and agenda for

  • Globe Newswire

    LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

    UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Presentation Details Format: Fireside

  • GlobeNewswire

    LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

    LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1LAVA-1266 on track for Q2 2024 IND submissionStrong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Compa